TL;DR
The dream of living for centuries in a young body rests on one idea above all: that old cells can be told to act young again. On Oct. 8, a Boston-area company reported the first human results from a therapy built to do exactly that, a one-time eye injection for glaucoma called ER-100. All three patients who got it had no serious side effects through eight weeks, two of the three did better on a vision test, and an independent safety board cleared a dose about three times higher, the company says. It is three people, with no comparison group, testing safety in one eye. But for the first time, the attempt to turn back the clock inside living human tissue has moved out of mouse papers and into patients, and it is moving up in dose.
Below the line, for paid subscribers: The full story: where it stands, how we got here and what's dated next; our Odds board on 5 milestones, starting with "Life Biosciences reports results from ER-100's higher-dose group by 2027"; our labeled speculation on what it adds up to; and every source.